Core Viewpoint - AMN Healthcare Services reported a decline in revenue and earnings for the quarter ended September 2025, with a notable surprise in EPS performance compared to analyst expectations [1][3]. Financial Performance - Revenue for the quarter was $634.5 million, down 7.7% year-over-year, but exceeded the Zacks Consensus Estimate of $615.14 million by 3.15% [1]. - Earnings per share (EPS) was $0.39, a decrease from $0.61 in the same quarter last year, but significantly higher than the consensus estimate of $0.19, resulting in an EPS surprise of 105.26% [1]. Segment Performance - Physician and leadership solutions reported revenue of $178.21 million, slightly above the average estimate of $175.12 million, but down 1.3% year-over-year [4]. - Nurse and allied solutions generated $361.48 million in revenue, surpassing the estimated $346.66 million, but reflecting a 9.5% decline compared to the previous year [4]. - Technology and workforce solutions achieved $94.81 million in revenue, exceeding the average estimate of $93.42 million, with an 11.8% year-over-year decrease [4]. Operating Income - Segment operating income for nurse and allied solutions was $28.76 million, above the estimated $24.57 million [4]. - Operating income for technology and workforce solutions was $30.89 million, below the average estimate of $33.09 million [4]. - Physician and leadership solutions had an operating income of $15.73 million, slightly above the estimated $15.37 million [4]. Stock Performance - AMN Healthcare shares returned 7.1% over the past month, outperforming the Zacks S&P 500 composite, which saw a 1.3% change [3]. - The stock currently holds a Zacks Rank of 5 (Strong Sell), indicating potential underperformance in the near term [3].

Financial Data and Key Metrics Changes - Third quarter revenue was $634 million, exceeding the high end of guidance by $9 million, but down 8% year-over-year and 4% sequentially [4][13] - Consolidated gross margin for Q3 was 29.1%, a decline of 190 basis points year-over-year and 70 basis points sequentially [13] - Adjusted EBITDA for Q3 was $57.5 million, representing 9.1% of revenue, which was 90 basis points above the high end of guidance [4][13] - Net income for Q3 was $29 million, compared to a net loss of $116 million in the prior quarter [19] Business Line Data and Key Metrics Changes - Nurse and Allied revenue was $361 million, down 9% year-over-year but exceeding guidance due to higher travel nurse volume and $12 million in labor disruption revenue [14] - Physician and Leadership Solutions segment revenue was $178 million, down 1% year-over-year but up 2% sequentially, with locum tenens revenue growing 3% year-over-year [16] - Technology and Workforce Solutions revenue was $95 million, down 12% year-over-year and 7% sequentially, primarily due to lower VMS revenue and the sale of SmartSquare [18] Market Data and Key Metrics Changes - Permanent hiring activity in the healthcare sector fell notably in Q3, indicating a shift towards more flexible workforce strategies [5] - The spread between travel nurse bill rates and fully loaded permanent nurse compensation is at a historical low, which may influence future hiring strategies [5] - Demand for travel nurses has increased by approximately 50% since mid-May, although it remains slightly below year-over-year levels [31] Company Strategy and Development Direction - The company aims to gain market share by enhancing technology, processes, and customer focus, with a strong emphasis on total talent solutions [11][41] - The strategy includes expanding service lines and improving fill rates, particularly in vendor-neutral programs [11][12] - The company expects to see more favorable revenue mix and growth in higher-margin businesses, particularly in international staffing [37] Management's Comments on Operating Environment and Future Outlook - Management noted that while the market remains competitive, there is rationality among competitors, and the focus is shifting towards total talent solutions [41] - The company anticipates modest year-over-year growth in nurse and allied revenue for Q4, with expectations for improved gross margins in 2026 [10][20] - Management expressed confidence in the recovery of demand and the ability to fill orders effectively, particularly as clients recognize the affordability of contingent labor [45][49] Other Important Information - The company completed a debt refinancing transaction, improving its financial position and extending the earliest debt expiration to 2029 [10][20] - Cash and equivalents as of September 30 were $53 million, with total debt at $850 million and a net leverage ratio of 3.3 times [19] Q&A Session Summary Question: Can you help us understand the drivers of gross margin guidance? - Management explained that the gross margin in Q3 was positively impacted by labor disruption, and the expected decline in Q4 is due to a mix of lower-margin revenue from certain segments [24][26] Question: What is the underlying performance of the business excluding labor disruption? - Management indicated that excluding labor disruption, the EBITDA margin would be in the mid-sixes range, reflecting the impact of the labor disruption event on overall performance [28] Question: Are the recent increases in demand due to winter orders or underlying improvements? - Management noted that demand has improved due to both seasonal factors and broader market conditions, with a significant recovery since mid-May [31] Question: How do you view the competitive landscape currently? - Management stated that while competition remains, it is rational, and there is a growing preference for total talent solutions among clients [41] Question: What are the expectations for clinician supply and demand? - Management reported a healthy supply of clinicians overall, with specific challenges in locums, and emphasized the importance of pricing orders correctly to fill them [56][58] Question: How is the company leveraging MSP relationships for locums? - Management highlighted intentional moves to support locums MSPs and noted significant improvements in fill rates for these clients [76][78]

Q3 2025 Financial Performance - Revenue for Q3 2025 was $634.5 million, compared to $687.5 million in Q3 2024, a decrease of 7.7%[9] - Gross profit for Q3 2025 was $184.4 million, with a gross margin of 29.1%, compared to $213.1 million and 31.0% respectively in Q3 2024[9] - Operating income for Q3 2025 was $47.6 million, resulting in an operating margin of 7.5%, compared to $22.3 million and 3.2% respectively in Q3 2024[9] - Net income for Q3 2025 was $29.3 million, or $0.76 per share, compared to $7.0 million, or $0.18 per share in Q3 2024[9] - Adjusted EBITDA for Q3 2025 was $57.5 million, with an adjusted EBITDA margin of 9.1%, compared to $73.9 million and 10.7% respectively in Q3 2024[9] Segment Performance - Nurse & Allied Solutions revenue was $361 million in Q3 2025, a 9.5% decrease year-over-year[9] - Physician & Leadership Solutions revenue was $175 million in Q3 2025, a 1.3% decrease year-over-year[9] - Technology & Workforce Solutions revenue was $95 million in Q3 2025, an 11.8% decrease year-over-year[9] Balance Sheet and Cash Flow - Cash and cash equivalents totaled $53 million as of September 30, 2025, compared to $42 million as of June 30, 2025[35] - Net cash provided by operating activities was $23 million in Q3 2025, compared to $67 million in Q3 2024[37] - Free cash flow was $15 million in Q3 2025, compared to $47 million in Q3 2024[37] Q4 2025 Financial Guidance - Consolidated revenue is projected to be between $715 million and $730 million[39] - Gross margin is expected to be between 25.5% and 26.0%[39] - Adjusted EBITDA margin is projected to be between 6.8% and 7.3%[39]

Core Insights - AMN Healthcare Services reported a year-on-year revenue decline of 7.7% to $634.5 million in Q3 CY2025, although it exceeded Wall Street expectations by 2.7% [6][7] - The company’s revenue guidance for the next quarter is $722.5 million at the midpoint, which is 16.4% above analysts' expectations [6][7] - Despite the revenue decline, AMN Healthcare's adjusted EPS of $0.39 was 95.2% above analysts' consensus estimates, although it represents a 10.5% annual decline [6][13] Revenue Performance - Over the last two years, AMN Healthcare's travelers on assignment averaged a 20.5% year-on-year decline, indicating a struggle with demand [1] - The company has experienced an 18.6% annual revenue decline over the past two years, reflecting a loss of previous gains [2] - AMN Healthcare's sales growth over the last five years was a modest 2.9% compounded annual growth rate, which is below industry standards [3] Profitability Metrics - The average operating margin for AMN Healthcare over the last five years was 7.1%, which is considered weak for a healthcare business [9] - The operating margin decreased by 20.2 percentage points over the last five years, indicating rising expenses that could not be passed onto customers [10] - In the latest quarter, the operating margin improved to 7.5%, up 4.3 percentage points year on year, suggesting improved efficiency despite revenue decline [11] Future Outlook - Company management is guiding for a 1.7% year-on-year decline in sales for the next quarter, while sell-side analysts expect a 7.3% revenue decline over the next 12 months [7] - The stock price increased by 5.3% to $19.40 immediately after the earnings report, indicating a positive market reaction despite underlying challenges [14]

Core Insights - AMN Healthcare Services reported third quarter 2025 revenue of $634 million, an 8% decrease year-over-year, with adjusted EBITDA of $58 million, reflecting a 22% decline from the previous year [1][4][10] - The company achieved a net income of $29 million, significantly up from $7 million in Q3 2024, resulting in diluted earnings per share of $0.76 compared to $0.18 a year ago [1][4][10] - The company anticipates fourth quarter 2025 revenue to be between $715 million and $730 million, with expectations of a sequential increase in travel nursing demand [14][15] Financial Performance - Consolidated revenue for Q3 2025 was $634.5 million, down 8% from Q3 2024 and down 4% from Q2 2025 [1][4] - Gross profit for the quarter was $184.4 million, a 13% decrease year-over-year, with a gross margin of 29.1% [1][9] - Adjusted diluted EPS was $0.39, down 36% from $0.61 in Q3 2024 [1][10] Segment Performance - Nurse and Allied Solutions segment revenue was $361 million, a 9% decrease year-over-year, with travel nurse staffing revenue down 20% [5][36] - Physician and Leadership Solutions segment reported revenue of $178 million, down 1% year-over-year, while locum tenens revenue increased by 3% [6][36] - Technology and Workforce Solutions segment revenue was $95 million, a decrease of 12% year-over-year, primarily due to the sale of Smart Square scheduling software [8][36] Operational Highlights - Cash flow from operations was $23 million, and the company paid off its revolving line of credit with proceeds from the sale of Smart Square totaling $65 million [6][11] - The company refinanced its senior unsecured notes due in 2027 with new notes due in 2031, enhancing financial flexibility [12][13] - Staffing orders rebounded in Q3, with winter order volume higher than the previous year, indicating potential growth in travel nursing for Q4 [4][6] Guidance and Outlook - For Q4 2025, the company expects revenue to be 1-3% lower than the prior year but up 13-15% sequentially [15] - Labor disruption revenue is projected at approximately $100 million, compared to $62 million in the prior-year quarter [15] - The company anticipates a gross margin of 25.5% to 26.0% for Q4, reflecting a decrease due to lower margins on labor disruption revenue [14][15]

Core Insights - Vivian Health and Hallmark Health Care Solutions have formed a strategic partnership to enhance the connection between healthcare agencies and clinicians, utilizing AI technology for improved hiring processes [2][4] - The integration of Vivian's AI-enabled hiring technology into Hallmark's platform aims to streamline the submission of clinician candidates, including travel nurses and allied health professionals [2][3] Company Overview - Vivian Health is the largest online marketplace for healthcare talent, serving over 2.5 million clinicians and offering more than 250,000 job opportunities [2][6] - Hallmark Health Care Solutions is a leader in workforce intelligence and enablement, managing over $10 billion in physician compensation annually and supporting more than 100,000 users daily [9][10] Technology and Efficiency - The integration allows for intelligent screening, automated profile generation, and one-click submissions, which enhances recruiter efficiency and improves conversion rates [3][4] - Vivian's AI Assistant is designed to help healthcare systems and agencies fill critical roles faster and more efficiently [7] Strategic Goals - The partnership aims to optimize the hiring process, reduce labor expenses, and maintain high-quality care in health systems [4][5] - Both companies are committed to advancing workforce solutions in the healthcare industry, focusing on better matching labor supply with demand [5][9]

Core Viewpoint - Cross Country Healthcare (NASDAQ: CCRN) experienced a 5% decline following news regarding the Federal Trade Commission's (FTC) review of its proposed sale to Aya Healthcare, valued at $615 million [2] Group 1 - The FTC is currently conducting a review of the planned transaction by deposing third parties involved in the process [2]

Core Points - AMN Healthcare Services, Inc. has scheduled a conference call to discuss its Q3 2025 financial results and Q4 2025 outlook on November 6, 2025, at 5:00 p.m. Eastern Time [1] - The earnings news release is expected to be issued after market close at approximately 4:15 p.m. Eastern Time on the same day [1] Access Information - A live webcast of the call will be available through a specific link and on AMN Healthcare's investor relations website [2] - Interested parties can participate live via telephone by registering at the conference call link, where a PIN will be provided for dial-in instructions [2] Replay Information - A replay of the webcast will be available on the Company's investor relations website following the conclusion of the call [3] Company Overview - AMN Healthcare is a leader in total talent solutions for healthcare, addressing workforce challenges to improve clinical outcomes and access to care [4] - In 2024, the Company's healthcare professionals reached nearly 15 million patients across more than 2,100 healthcare systems, including 87% of the top healthcare systems nationwide [4] - The Company offers a comprehensive network of quality healthcare professionals and a fully integrated suite of customizable workforce technologies [4] Stock Information - The Company's common stock is listed under the symbol "AMN" on the New York Stock Exchange [5] - For more information, the Company provides news releases, investor presentations, webcasts, SEC filings, and other material information on its website [5]

Core Points - AMN Healthcare Services, Inc. announced a private offering of $400 million senior unsecured notes due 2031 with an interest rate of 6.500% per annum [1] - The proceeds will be used to redeem $500 million of 4.625% senior unsecured notes due 2027 and to cover related fees and expenses [2] - A Conditional Notice of Redemption has been delivered for the 2027 Notes, with redemption scheduled for October 22, 2025, contingent on the successful completion of the 2031 Notes offering [3] - The 2031 Notes will be offered to qualified institutional buyers and non-U.S. persons, and will not be registered under the Securities Act [4] Company Overview - AMN Healthcare is a leader in total talent solutions for healthcare, addressing workforce challenges to improve clinical outcomes [6] - In 2024, AMN Healthcare professionals reached nearly 15 million patients across over 2,100 healthcare systems, including 87% of the top healthcare systems in the U.S. [6]

Core Viewpoint - AMN Healthcare Services, Inc. plans to offer $400 million in senior unsecured notes due 2031 to refinance existing debt and cover related expenses [1][2][3] Group 1: Offering Details - The company intends to use proceeds from the new offering, along with cash and borrowings, to redeem $500 million of its 4.625% senior unsecured notes due 2027 [2] - A Conditional Notice of Redemption will be sent to holders of the 2027 Notes, contingent on the successful completion of the 2031 Notes offering [3] - The 2031 Notes will be offered to qualified institutional buyers and non-U.S. persons, and will not be registered under the Securities Act [4] Group 2: Company Overview - AMN Healthcare is a leader in total talent solutions for healthcare, addressing workforce challenges to improve clinical outcomes [6] - In 2024, AMN Healthcare professionals served nearly 15 million patients across over 2,100 healthcare systems, including 87% of the top healthcare systems in the U.S. [6]